| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 185.000 +9.20% on 03/21/24 | | 209.500 -3.57% on 04/11/24 | +15.427 (+8.27%) since 03/19/24 |
| 3-Month | 167.000 +20.97% on 03/04/24 | | 220.000 -8.17% on 03/11/24 | +21.227 (+11.74%) since 01/19/24 |
| 52-Week | 164.288 +22.97% on 12/01/23 | | 474.500 -57.42% on 06/15/23 | -236.973 (-53.98%) since 04/19/23 |
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy Oxford, UK – 26 July 2022: Oxford...
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology Oxford, UK – 26 July 2022: Oxford Biomedica plc...
Oxford Biomedica plcPreliminary results for the year ended 31 December 2021 Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE: OXB),...
Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK –...
BEDFORD, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the successful...
Oxford Biomedica announces that Sio Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease Negligible...
Virica Biotech Inc. , a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy company,...
John Dawson to retire from Oxford Biomedica Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group” or “the...
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK – 19...
The information contained within thi s announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic...
| 3rd Resistance Point | 225.000 |
| 2nd Resistance Point | 215.000 |
| 1st Resistance Point | 210.000 |
| Last Price | 202.027 |
| 1st Support Level | 195.000 |
| 2nd Support Level | 185.000 |
| 3rd Support Level | 180.000 |
| 52-Week High | 474.500 |
| Fibonacci 61.8% | 355.999 |
| Fibonacci 50% | 319.394 |
| Fibonacci 38.2% | 282.789 |
| Last Price | 202.027 |
| 52-Week Low | 164.288 |